Literature DB >> 19266260

HRCT and scleroderma: semiquantitative evaluation of lung damage and functional abnormalities.

M Bellia1, F Cannizzaro, N Scichilone, M Riili, G Triolo, M Midiri, R Lagalla.   

Abstract

PURPOSE: This study sought to validate the Warrick score in the assessment of lung involvement in systemic sclerosis (SSc) and correlate the results with functional abnormalities. In addition, we propose the use of high resolution computed tomography (HRCT) indices of alveolitis and fibrosis to discriminate between different stages of the disease.
MATERIALS AND METHODS: Thirty-one patients with SSc (16 with the diffuse form and 15 with the limited form) underwent functional and HRCT evaluations of the lung. The semiquantitative evaluation of radiological involvement, as proposed by Warrick, provides a score for each lesion based on the severity and the extent of the pulmonary damage. In addition to the total score, indices for alveolitis and fibrosis were created. The association between each score and functional abnormalities was tested.
RESULTS: The total Warrick score was 16+/-7.7 [mean+/-standard deviation (SD)]. The total score correlated inversely with total lung capacity (TLC) (percentage of predicted TLC) (r=-0.38; p=0.04), diffusion lung capacity for carbon monoxide (DLCO) (percentage of predicted DLCO) (r=-0.43; p=0.02) and with forced expiratory volume in 1 second (FEV1) (percentage of predicted FEV1) (r=-0.36; p=0.05). The alveolitis and fibrosis indices were 1.9+/-1.1 and 14.2+/-7.4, respectively. The alveolitis index correlated significantly with percentage of predicted DLCO (r=-0.46; p=0.01) but not with percentage of predicted TLC (r=-0.28; p=0.13). The fibrosis index correlated both with percentage of predicted DLCO (r=-0.38; p=0.04) and with percentage of predicted TLC (r=-0.35; p=0.05).
CONCLUSIONS: Our findings confirm the diagnostic role of HRCT in assessing the extent of lung damage in SSc. Furthermore, the two indices (alveolitis and fibrosis) provide new tools for evaluating the relationship between pulmonary involvement and systemic impairment in SSc.

Entities:  

Mesh:

Year:  2009        PMID: 19266260     DOI: 10.1007/s11547-009-0367-9

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  19 in total

1.  [Lung fibrosis quantified by HRCT in scleroderma patients with different disease forms and ANA specificities]

Authors:  F. Cozzi; M. Chiesura Corona; M. Rizzi; C. Dus; N. Durigon; S. Mancin; S. Todesco
Journal:  Reumatismo       Date:  2001

2.  Bronchiectasis in systemic sclerosis. A study using high resolution computed tomography.

Authors:  A P Andonopoulos; S Yarmenitis; P Georgiou; A Bounas; C Vlahanastasi
Journal:  Clin Exp Rheumatol       Date:  2001 Mar-Apr       Impact factor: 4.473

3.  Bronchiectasis in a patient with CREST syndrome.

Authors:  Frédéric Lavie; Sylvie Rozenberg; Anne Coutaux; Anne-Claude Koeger; Pierre Bourgeois; Bruno Fautrel
Journal:  Joint Bone Spine       Date:  2002-10       Impact factor: 4.929

4.  Pulmonary scleroderma.

Authors:  A L Weaver; M B Divertie; J L Titus
Journal:  Dis Chest       Date:  1968-12

5.  Bronchoalveolar lavage for evaluation and management of scleroderma disease of the lung.

Authors:  J Behr; C Vogelmeier; T Beinert; M Meurer; F Krombach; G König; G Fruhmann
Journal:  Am J Respir Crit Care Med       Date:  1996-08       Impact factor: 21.405

6.  Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee.

Authors: 
Journal:  Arthritis Rheum       Date:  1980-05

7.  [Lung interstitial disease in systemic sclerosis: semiologic characteristics with high-resolution computerized tomography and comparison with other methods].

Authors:  A Rotondo; R Grassi; O Catalano; L Del Viscovo; M Vatti; M Gallo; L Bianco; L Celentano; A Brunetti; M Rivellini
Journal:  Radiol Med       Date:  1993-09       Impact factor: 3.469

8.  The predictive value of appearances on thin-section computed tomography in fibrosing alveolitis.

Authors:  A U Wells; D M Hansell; M B Rubens; P Cullinan; C M Black; R M du Bois
Journal:  Am Rev Respir Dis       Date:  1993-10

9.  High resolution computed tomography in early scleroderma lung disease.

Authors:  J H Warrick; M Bhalla; S I Schabel; R M Silver
Journal:  J Rheumatol       Date:  1991-10       Impact factor: 4.666

10.  Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis.

Authors:  Philip J Clements; Jonathan G Goldin; Eric C Kleerup; Daniel E Furst; Robert M Elashoff; Donald P Tashkin; Michael D Roth
Journal:  Arthritis Rheum       Date:  2004-06
View more
  4 in total

1.  Quantitative volumetric assessment of pulmonary involvement in patients with systemic sclerosis.

Authors:  Mehmet Güli Çetinçakmak; Cemil Göya; Cihad Hamidi; Güven Tekbaş; Özlem Abakay; İbrahim Batmaz; Salih Hattapoğlu; Alpaslan Yavuz; Aslan Bilici
Journal:  Quant Imaging Med Surg       Date:  2016-02

2.  High-resolution computed tomography and rheumatoid arthritis: semi-quantitative evaluation of lung damage and its correlation with clinical and functional abnormalities.

Authors:  Baris Yilmazer; Sevtap Gümüştaş; Fulya Coşan; Nagihan İnan; Fatih Ensaroğlu; Gökhan Erbağ; Füsun Yıldız; Ayşe Çefle
Journal:  Radiol Med       Date:  2015-10-22       Impact factor: 3.469

3.  Pulmonary hypertension and systemic sclerosis: the role of high-resolution computed tomography.

Authors:  Maurizio Zompatori; Maria Barbara Leone; Marica Giannotta; Nazzareno Galiè; Massimiliano Palazzini; Maria Letizia Bacchi Reggiani; Lea Bono; Gian Stefano Pollini
Journal:  Radiol Med       Date:  2013-05-27       Impact factor: 3.469

4.  Abatacept in rheumatoid arthritis-associated interstitial lung disease: short-term outcomes and predictors of progression.

Authors:  Marika Tardella; Marco Di Carlo; Marina Carotti; Andrea Giovagnoni; Fausto Salaffi
Journal:  Clin Rheumatol       Date:  2021-07-27       Impact factor: 2.980

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.